{"id":"W2950083834","doi":"10.1136/annrheumdis-2019-eular.1719","title":"OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS— RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; University of Toronto","funders":"National Institutes of Health; CSL Behring; Genentech; Acceleron; United Therapeutics Corporation; Sanofi; National Institute of Allergy and Infectious Diseases; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Double blind; Abatacept; Placebo; Randomized controlled trial; Scleroderma (fungus); Internal medicine; Multicenter study; Systemic scleroderma; Pathology; Alternative medicine; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002636947,0.002449979,0.004976682,0.0006655272,0.0005325802,0.001406442,0.001259061,0.002525648,0.005406772],"category_scores_gemma":[0.00173489,0.0007177072,0.002447531,0.0005648758,0.001380112,0.001403496,0.0004459239,0.003531173,0.001179489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006107818,"about_ca_system_score_gemma":0.001288561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000894642,"about_ca_topic_score_gemma":0.001639704,"domain_scores_codex":[0.9990799,0.0004338435,0.00005834921,0.0001597963,0.0001014762,0.000166531],"domain_scores_gemma":[0.9990798,0.0002957686,0.0001714557,0.0000689823,0.00007674687,0.0003071606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9694141,0.00641684,0.0003744202,0.0008483875,0.0006628783,0.00005846133,0.00003867151,0.0001933456,0.003503536,0.00008018334,0.000669772,0.01773944],"study_design_scores_gemma":[0.9682502,0.03014452,0.0008113075,0.00002180453,0.0002084524,0.00001785352,0.000008906341,0.0001298757,0.0001514684,0.00004736905,0.0001997915,0.000008499625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762198,0.01079658,0.001595521,0.0008091722,0.0009464251,0.005140395,0.001636764,0.0003233475,0.002532],"genre_scores_gemma":[0.9701964,0.007609974,0.00397638,0.002387002,0.001486904,0.006422493,0.002596277,0.00007937829,0.005245266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005406772,"threshold_uncertainty_score":0.01808745,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06634695926808125,"score_gpt":0.3262672122342755,"score_spread":0.2599202529661942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}